(IPN) Ipsen - Overview
Stock: Oncology, Rare Disease, Neuroscience, Biopharmaceuticals, Therapeutics
Dividends
| Dividend Yield | 1.34% |
| Yield on Cost 5y | 2.01% |
| Yield CAGR 5y | 8.78% |
| Payout Consistency | 97.4% |
| Payout Ratio | 26.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 23.1% |
| Relative Tail Risk | -3.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.54 |
| Alpha | 8.64 |
| Character TTM | |
|---|---|
| Beta | 0.037 |
| Beta Downside | 0.250 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.25% |
| CAGR/Max DD | 0.33 |
Description: IPN Ipsen January 06, 2026
Ipsen S.A. is a French-based biopharmaceutical company that develops and markets medicines across three therapeutic pillars – oncology, rare disease, and neuroscience – serving patients worldwide. The firm trades on Euronext under the ticker IPN.
In oncology, Ipsen’s commercial portfolio includes Somatuline (for neuroendocrine tumors and acromegaly), Cabometyx (TKI for second-line neuroendocrine tumors), Onivyde (liposomal irinotecan for pancreatic cancer), Decapeptyl (advanced prostate cancer), and Tazverik (EZH2 inhibitor in Phase III for follicular lymphoma). Late-stage pipeline assets comprise Tovorafenib (Phase III first-line pediatric LGG; Phase II relapsed/refractory LGG) and early-stage candidates IPN01194/01195 (Phase I solid tumors).
In the rare-disease segment, Ipsen markets Bylvay (progressive familial intrahepatic cholestasis), Iqirvo (primary biliary cholangitis), NutropinAq (recombinant human growth hormone), and Increlex (IGF-1). Mid-stage programs include Fidrisertib (Phase II fibrodysplasia ossificans progressive) and Ritivixibat (Phase II primary sclerosing cholangitis).
Neuroscience offerings feature Dysport (botulinum toxin) – currently in Phase III for chronic and episodic migraine – and IPN10200, a pipeline candidate in Phase II for aesthetic and therapeutic indications.
Key financial and market drivers (2023 data):
• Revenue of approximately €2.9 billion, with oncology contributing roughly 50 % of sales.
• R&D expenditure of about €500 million, representing ~17 % of revenue, underscoring a strong pipeline investment.
• The global oncology drug market is projected to grow at a CAGR of ~8 % through 2030, providing tailwinds for Ipsen’s growth, while rare-disease therapies benefit from premium pricing and expanding patient-access programs in Europe and the U.S.
For a deeper quantitative view of Ipsen’s valuation dynamics, see the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 1.13b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 6.13 > 1.0 |
| NWC/Revenue: 19.98% < 20% (prev 8.28%; Δ 11.70% < -1%) |
| CFO/TA 0.27 > 3% & CFO 1.88b > Net Income 1.13b |
| Net Debt (-483.2m) to EBITDA (2.50b): -0.19 < 3 |
| Current Ratio: 1.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (83.5m) vs 12m ago -0.01% < -2% |
| Gross Margin: 82.18% > 18% (prev 0.83%; Δ 8134 % > 0.5%) |
| Asset Turnover: 106.2% > 50% (prev 51.90%; Δ 54.31% > 0%) |
| Interest Coverage Ratio: 35.84 > 6 (EBITDA TTM 2.50b / Interest Expense TTM 50.0m) |
Altman Z'' 8.56
| A: 0.20 (Total Current Assets 2.81b - Total Current Liabilities 1.42b) / Total Assets 6.83b |
| B: 0.61 (Retained Earnings 4.19b / Total Assets 6.83b) |
| C: 0.27 (EBIT TTM 1.79b / Avg Total Assets 6.58b) |
| D: 3.23 (Book Value of Equity 8.39b / Total Liabilities 2.60b) |
| Altman-Z'' Score: 8.56 = AAA |
Beneish M -2.72
| DSRI: 0.66 (Receivables 958.0m/686.5m, Revenue 6.99b/3.28b) |
| GMI: 1.01 (GM 82.18% / 83.07%) |
| AQI: 0.81 (AQ_t 0.49 / AQ_t-1 0.61) |
| SGI: 2.13 (Revenue 6.99b / 3.28b) |
| TATA: -0.11 (NI 1.13b - CFO 1.88b) / TA 6.83b) |
| Beneish M-Score: -2.72 (Cap -4..+1) = A |
What is the price of IPN shares?
Over the past week, the price has changed by -1.09%, over one month by +12.48%, over three months by +10.56% and over the past year by +13.53%.
Is IPN a buy, sell or hold?
What are the forecasts/targets for the IPN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 132.7 | -2.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 149.4 | 9.8% |
IPN Fundamental Data Overview February 03, 2026
P/E Trailing = 25.5866
P/E Forward = 13.8504
P/S = 3.0113
P/B = 2.6611
P/EG = 0.7845
Revenue TTM = 6.99b EUR
EBIT TTM = 1.79b EUR
EBITDA TTM = 2.50b EUR
Long Term Debt = 745.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 123.7m EUR (from shortTermDebt, last quarter)
Debt = 961.8m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -483.2m EUR (from netDebt column, last quarter)
Enterprise Value = 10.84b EUR (11.32b + Debt 961.8m - CCE 1.45b)
Interest Coverage Ratio = 35.84 (Ebit TTM 1.79b / Interest Expense TTM 50.0m)
EV/FCF = 6.88x (Enterprise Value 10.84b / FCF TTM 1.57b)
FCF Yield = 14.53% (FCF TTM 1.57b / Enterprise Value 10.84b)
FCF Margin = 22.54% (FCF TTM 1.57b / Revenue TTM 6.99b)
Net Margin = 16.16% (Net Income TTM 1.13b / Revenue TTM 6.99b)
Gross Margin = 82.18% ((Revenue TTM 6.99b - Cost of Revenue TTM 1.25b) / Revenue TTM)
Gross Margin QoQ = 82.14% (prev 83.43%)
Tobins Q-Ratio = 1.59 (Enterprise Value 10.84b / Total Assets 6.83b)
Interest Expense / Debt = 1.63% (Interest Expense 15.7m / Debt 961.8m)
Taxrate = 21.06% (89.5m / 425.0m)
NOPAT = 1.41b (EBIT 1.79b * (1 - 21.06%))
Current Ratio = 1.98 (Total Current Assets 2.81b / Total Current Liabilities 1.42b)
Debt / Equity = 0.23 (Debt 961.8m / totalStockholderEquity, last quarter 4.23b)
Debt / EBITDA = -0.19 (Net Debt -483.2m / EBITDA 2.50b)
Debt / FCF = -0.31 (Net Debt -483.2m / FCF TTM 1.57b)
Total Stockholder Equity = 4.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.17% (Net Income 1.13b / Total Assets 6.83b)
RoE = 27.74% (Net Income TTM 1.13b / Total Stockholder Equity 4.07b)
RoCE = 37.21% (EBIT 1.79b / Capital Employed (Equity 4.07b + L.T.Debt 745.6m))
RoIC = 29.95% (NOPAT 1.41b / Invested Capital 4.72b)
WACC = 5.68% (E(11.32b)/V(12.28b) * Re(6.05%) + D(961.8m)/V(12.28b) * Rd(1.63%) * (1-Tc(0.21)))
Discount Rate = 6.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.01%
[DCF Debug] Terminal Value 87.46% ; FCFF base≈1.37b ; Y1≈1.55b ; Y5≈2.10b
Fair Price DCF = 755.3 (EV 61.74b - Net Debt -483.2m = Equity 62.23b / Shares 82.4m; r=5.90% [WACC]; 5y FCF grow 15.13% → 2.90% )
EPS Correlation: -22.56 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 75.06 | Revenue CAGR: 55.75% | SUE: 1.09 | # QB: 1
EPS next Year (2026-12-31): EPS=11.80 | Chg30d=+0.531 | Revisions Net=+3 | Growth EPS=+2.0% | Growth Revenue=+5.8%